trial · primary record
Daratumumab
Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 214 |
| Primary completion | 2029-01-31 |
| Primary endpoint | Number of Participants with Serious Adverse Events (SAEs) |
| Registry ID | NCT05438043 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:48.553Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05438043
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Daratumumab · approval
- Daratumumab · compound